



1

SEQUENCE LISTING

<110> KRIEG, PAUL A.

<120> METHODS FOR MODULATING ANGIOGENESIS WITH APELIN COMPOSITIONS

<130> 20825-0004

<140> 10/799,417

<141> 2004-03-12

<150> 60/454,034

<151> 2003-03-12

<150> 60/528,155

<151> 2003-12-09

<160> 21

<170> PatentIn Ver. 3.2

<210> 1

<211> 77

<212> PRT

<213> Homo sapiens

<400> 1

Met Asn Leu Arg Leu Cys Val Gln Ala Leu Leu Leu Leu Trp Leu Ser
1 5 10 15Leu Thr Ala Val Cys Gly Gly Ser Leu Met Pro Leu Pro Asp Gly Asn
20 25 30Gly Leu Glu Asp Gly Asn Val Arg His Leu Val Gln Pro Arg Gly Ser
35 40 45Arg Asn Gly Pro Gly Pro Trp Gln Gly Gly Arg Arg Lys Phe Arg Arg
50 55 60Gln Arg Pro Arg Leu Ser His Lys Gly Pro Met Pro Phe
65 70 75

<210> 2

<211> 36

<212> PRT

<213> Homo sapiens

<400> 2

Leu Val Gln Pro Arg Gly Ser Arg Asn Gly Pro Gly Pro Trp Gln Gly
1 5 10 15Gly Arg Arg Lys Phe Arg Arg Gln Arg Pro Arg Leu Ser His Lys Gly
20 25 30Pro Met Pro Phe
35

<210> 3
<211> 17
<212> PRT
<213> Homo sapiens

<400> 3
Lys Phe Arg Arg Gln Arg Pro Arg Leu Ser His Lys Gly Pro Met Pro
1 5 10 15

Phe

<210> 4
<211> 13
<212> PRT
<213> Homo sapiens

<400> 4
Gln Arg Pro Arg Leu Ser His Lys Gly Pro Met Pro Phe
1 5 10

<210> 5
<211> 13
<212> PRT
<213> Brachydanio rerio

<400> 5
Pro Arg Pro Arg Leu Ser His Lys Gly Pro Met Pro Phe
1 5 10

<210> 6
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 6
gtgcccaaag tctgagattc atgtt 25

<210> 7
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 7
gattcatgtt tcttgtggct gagtg 25

<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 8
gattgatctt tgttgtgcct cagtg 25

<210> 9
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 9
aaggctgtgt ggaagcaata gaaag 25

<210> 10
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 10
aaggcctctgt gcaaccaata caaag 25

<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic consensus sequence

<400> 11
Asx Ala Cys Gly Thr Gly Lys
1 5

<210> 12
<211> 10
<212> DNA
<213> Homo sapiens

<400> 12
gagacgttggaa

10

<210> 13
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 13
cagacgttgac a

11

<210> 14
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 14
tgtacgttgg

9

<210> 15
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 15
aatgacgtga tg

12

<210> 16
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 16
tacgtggg

8

<210> 17

<211> 380

<212> PRT

<213> Homo sapiens

<400> 17

Met	Glu	Glu	Gly	Gly	Asp	Phe	Asp	Asn	Tyr	Tyr	Gly	Ala	Asp	Asn	Gln
1									10						15

Ser	Glu	Cys	Glu	Tyr	Thr	Asp	Trp	Lys	Ser	Ser	Gly	Ala	Leu	Ile	Pro
									20	25				30	

Ala	Ile	Tyr	Met	Leu	Val	Phe	Leu	Leu	Gly	Thr	Thr	Gly	Asn	Gly	Leu
									35	40			45		

Val	Leu	Trp	Thr	Val	Phe	Arg	Ser	Ser	Arg	Glu	Lys	Arg	Arg	Ser	Ala
									50	55			60		

Asp	Ile	Phe	Ile	Ala	Ser	Leu	Ala	Val	Ala	Asp	Leu	Thr	Phe	Val	Val
65									70		75			80	

Thr	Leu	Pro	Leu	Trp	Ala	Thr	Tyr	Thr	Tyr	Arg	Asp	Tyr	Asp	Trp	Pro
									85	90			95		

Phe	Gly	Thr	Phe	Phe	Cys	Lys	Leu	Ser	Ser	Tyr	Leu	Ile	Phe	Val	Asn
									100	105			110		

Met	Tyr	Ala	Ser	Val	Phe	Cys	Leu	Thr	Gly	Leu	Ser	Phe	Asp	Arg	Tyr
									115	120			125		

Leu	Ala	Ile	Val	Arg	Pro	Val	Ala	Asn	Ala	Arg	Leu	Arg	Leu	Arg	Val
									130	135			140		

Ser	Gly	Ala	Val	Ala	Thr	Ala	Val	Leu	Trp	Val	Leu	Ala	Ala	Leu	Leu
145									150		155			160	

Ala	Met	Pro	Val	Met	Val	Leu	Arg	Thr	Thr	Gly	Asp	Leu	Glu	Asn	Thr
									165	170			175		

Thr	Lys	Val	Gln	Cys	Tyr	Met	Asp	Tyr	Ser	Met	Val	Ala	Thr	Val	Ser
									180	185			190		

Ser	Glu	Trp	Ala	Trp	Glu	Val	Gly	Leu	Gly	Val	Ser	Ser	Thr	Thr	Val
									195	200			205		

Gly	Phe	Val	Val	Pro	Phe	Thr	Ile	Met	Leu	Thr	Cys	Tyr	Phe	Phe	Ile
									210	215			220		

Ala	Gln	Thr	Ile	Ala	Gly	His	Phe	Arg	Lys	Glu	Arg	Ile	Glu	Gly	Leu
									225	230			235		240

Arg	Lys	Arg	Arg	Arg	Leu	Leu	Ser	Ile	Ile	Val	Val	Leu	Val	Val	Thr
									245	250			255		

Phe	Ala	Leu	Cys	Trp	Met	Pro	Tyr	His	Leu	Val	Lys	Thr	Leu	Tyr	Met
									260	265			270		

Leu Gly Ser Leu Leu His Trp Pro Cys Asp Phe Asp Leu Phe Leu Met
 275 280 285

Asn Ile Phe Pro Tyr Cys Thr Cys Ile Ser Tyr Val Asn Ser Cys Leu
 290 295 300

Asn Pro Phe Leu Tyr Ala Phe Phe Asp Pro Arg Phe Arg Gln Ala Cys
 305 310 315 320

Thr Ser Met Leu Cys Cys Gly Gln Ser Arg Cys Ala Gly Thr Ser His
 325 330 335

Ser Ser Ser Gly Glu Lys Ser Ala Ser Tyr Ser Ser Gly His Ser Gln
 340 345 350

Gly Pro Gly Pro Asn Met Gly Lys Gly Glu Gln Met His Glu Lys
 355 360 365

Ser Ile Pro Tyr Ser Gln Glu Thr Leu Val Val Asp
 370 375 380

<210> 18

<211> 14

<212> PRT

<213> Rana sp.

<400> 18

Arg Gln Arg Pro Arg Leu Ser His Lys Gly Pro Met Pro Phe
 1 5 10

<210> 19

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 consensus sequence

<400> 19

Arg Gln Arg Pro Arg Leu Ser His Lys Gly Pro Met Pro Phe
 1 5 10

<210> 20

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 peptide

<400> 20

Lys Lys Lys Arg
 1

<210> 21
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 21
Arg Arg Arg Arg
1